{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"description":"VGPR defined as any one of the following:\n\n≥ 90% reduction of serum M-protein; ≥ 90% reduction in 24-hour urinary M-protein or decrease to \\< 100 mg per 24 hour; ≥ 50% decrease in the difference between involved and uninvolved FLC levels or a 50% decrease in level of involved FLC with 50% decrease in ratio; ≥ 50% reduction in bone marrow plasma cells; ≥ 50% reduction in the size of soft tissue plasmacytomas.","groups":[{"description":"All patients who receive transplant in the phase 1+2 of the study","id":"OG000","title":"Patients Undergoing Transplantation"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients who underwent transplantation","reportingStatus":"POSTED","timeFrame":"Up to 17 months","title":"Very Good Partial Response (VGPR) Rate.","type":"PRIMARY","unitOfMeasure":"Participants"}